Endothelial progenitor cells in pulmonary hypertension – dawn of cell‐based therapy?

  title={Endothelial progenitor cells in pulmonary hypertension – dawn of cell‐based therapy?},
  author={M. Toshner and N. W Morrell},
  journal={International Journal of Clinical Practice},
  • M. Toshner, N. W Morrell
  • Published 2010
  • Medicine
  • International Journal of Clinical Practice
  • There is mounting interest in the concept of endothelial progenitor cell (EPC) therapy for the treatment of pulmonary arterial hypertension (PAH). Recent successful pilot studies in idiopathic PAH have raised questions about the contribution of progenitor cells circulating in the peripheral blood to pulmonary vascular homeostasis and to the process of vascular remodelling. This review will summarise the work performed to date in animal and human therapeutic trials and clarify what is known… CONTINUE READING
    17 Citations

    Topics from this paper.

    The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease
    • 1
    • Highly Influenced
    Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow-induced pulmonary arterial hypertension in rabbits.
    • 11
    • Highly Influenced
    Vascular progenitor cells in chronic obstructive pulmonary disease.
    • 12
    Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension.
    • 25
    Estrogen metabolism in pulmonary arterial hypertension
    Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.
    • 90
    Programmatic change: lung disease research in the era of induced pluripotency.
    • 5
    • PDF


    Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension.
    • 182
    • PDF
    Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.
    • 230
    • PDF